Sofosbuvir/simeprevir versus sofosbuvir/ribavirin regimen in Egyptian patients with hepatitis C virus

Sara M. Abdelhakam; Nevine I. Musa; Moataz M. Sayed; Shereen A. Saleh; Marwa Rushdy

doi:10.1097/01.elx.0000530963.88208.f4

Citations

391

Views

Abstract not available for this publication.

Cite this Article (APA)

Sara, M. A., Nevine, I. M., Moataz, M. S., Shereen, A. S., Marwa, R. (2018). Sofosbuvir/simeprevir versus sofosbuvir/ribavirin regimen in Egyptian patients with hepatitis C virus. Egyptian Liver Journal. https://doi.org/10.1097/01.elx.0000530963.88208.f4

Gamal Shiha; Seham Seif; Maha Maher; Shahera Etreby; Waleed Samir; Khaled Zalata · 2014

cites

389

Tissue microarray as a research tool to study non-neoplastic liver diseases

Mohamed H. Abdel-Rahman; Ahmad A. Agour; Dina S. El-Azab · 2014

cites

388

Prevalence of hepatitis C virus seroconversion among hemodialysis patients in Egypt

Iman I. Sarhan; Cherry R. Kamel · 2015

cites

391

Prevention of paracentesis-induced circulatory dysfunction